NCT01557660撤回3 期
Inhaled Treprostinil in Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, International, Multi-Center Study
United Therapeutics0 个研究点开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 主要终点
- Long term safety of inhaled treprostinil
研究概览
简要总结
Open-label extension of RIN-PH-302.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
inhaled treprostinil
Experimental
干预措施: inhaled treprostinil (Drug)
结局指标
主要结局
Long term safety of inhaled treprostinil
时间窗: up to 5 years
次要结局
- Six-minute walk distance(up to 5 years)
研究者
相似试验
Enrolling By Invitation
3 期
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseIdiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisInterstitial Lung DiseaseIdiopathic Pulmonary FibrosisInterstitial Lung DiseaseNCT04905693United Therapeutics1,850
终止
3 期
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)Pulmonary HypertensionChronic Obstructive Pulmonary DiseaseNCT03794583United Therapeutics41
尚未招募
3 期
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary FibrosisNL-OMON56110nited Therapeutics Corp.16
招募中
1 期
Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung DiseaseFibrotic Lung DiseaseMedDRA version: 20.0Level: LLTClassification code: 10025089Term: Lung fibrosis interstitial Class: 10038738CTIS2023-504471-25-00nited Therapeutics Corp.1,850
Unknown
不适用
LenusPro Pump in PAH Treated With TreprostinilPulmonary Arterial HypertensionNCT02889315Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center for Postgraduate Med20